Abstract Tebentafusp is a novel T-cell receptor–bispecific protein that targets glycoprotein 100 and CD3. It is the only approved systemic therapy for patients with unresectable or metastatic HLA-A*02:01 positive uveal melanoma. Cutaneous toxicities are common, yet there are limited studies in the literature. We conducted a retrospective observational cohort study of patients with HLA-A*02:01- positive unresectable or metastatic uveal melanoma at our tertiary referral centre, who received tebentafusp therapy from August 2021 to January 2024. Cutaneous toxicity occurred in 89% of patients, but reactions were manageable with no patients permanently discontinuing treatment. To our knowledge, we also report the first case of bullous pemphigoid associated with tebentafusp.
Wang et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: